SCHEMBL682288

SCHEMBL682288

COC(=O)[C@@H]1CCCN1C(=O)C(C)S

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PEPD P12955 3/20 0.52
XPNPEP1 Q9NQW7 1/20 0.52
POLB P06746 1/20 0.51
ACE P12821 6/20 0.48
REN P00797 4/20 0.48
KDM4E B2RXH2 1/20 0.48
F2 P00734 1/20 0.48
LMNA P02545 1/20 0.48
LTA4H P09960 1/20 0.48
MAPT P10636 1/20 0.48
ALOX15 P16050 1/20 0.48
PTGS1 P23219 1/20 0.48
HTR2A P28223 1/20 0.48
PTGS2 P35354 1/20 0.48
HRH1 P35367 1/20 0.48
THPO P40225 1/20 0.48
PMP22 Q01453 1/20 0.48
HSD17B10 Q99714 1/20 0.48
ACE2 Q9BYF1 1/20 0.48
FKBP1A P62942 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13921121 0.87 PEPD (0.54) PEPDXPNPEP1POLBACEREN
SCHEMBL17040270 0.87 PEPD (0.54) PEPDXPNPEP1POLBACEREN
SCHEMBL20471043 0.87 PEPD (0.54) PEPDXPNPEP1POLBACEREN
SCHEMBL9532959 0.84 PEPD (0.59) PEPDXPNPEP1POLBACEREN
SCHEMBL6374536 0.84 PEPD (0.59) PEPDXPNPEP1POLBACEREN
SCHEMBL17037452 0.84 PEPD (0.52) PEPDXPNPEP1POLBACEREN
SCHEMBL28594897 0.84 PEPD (0.59) PEPDXPNPEP1POLBACEREN
SCHEMBL17037454 0.84 PEPD (0.52) PEPDXPNPEP1POLBACEREN
SCHEMBL7382198 0.84 PEPD (0.47) PEPDXPNPEP1POLBACEREN
SCHEMBL21533006 0.83 ACE (0.71) PEPDXPNPEP1POLBACEREN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110269717-A1 NEUROGENESIS BY MODULATING ANGIOTENSIN BRAINCELLS INC. (US) 2011-11-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110269717-A1 NEUROGENESIS BY MODULATING ANGIOTENSIN NGF, DCX, BDNF PEPD 366/4885XPNPEP1 1365/4885POLB 1723/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.